Long-term medication use and follow-up visits are the main drivers affecting costs associated with cancer-related bisphosphonate-associated osteonecrosis of the jaw, report researchers in Oral Diseases.
[More]
Researchers have linked Perthes' disease with several congenital conditions, pointing to intra-uterine factors behind the development of the disease.
[More]
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
[More]
Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
[More]
During the early developmental stages of vertebrates-animals that have a backbone and spinal column, including humans-cells undergo extensive rearrangements, and some cells migrate over large distances to populate particular areas and assume novel roles as differentiated cell types.
[More]
The risk for developing osteonecrosis of the jaw after a tooth extraction is significantly higher among patients who receive bisphosphonates than those who do not, suggest study findings.
[More]
What's the latest, research-supported best practice in periodontal care and implant dentistry? Dental specialists and generalists alike can read about it in the first of a new series from The Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, published by Elsevier.
[More]
Children diagnosed with juvenile dermatomyositis at age 3 years or earlier have milder symptoms than patients with later onset, research suggests.
[More]
Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
[More]
Use of osteoporosis investigation and treatment is significantly increased in older patients with asymptomatic vertebral fracture by use of physician- and patient-targeted interventions, Canadian research suggests.
[More]
Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results.
[More]
Older patients with breast cancer may benefit from adjuvant treatment with oral bisphosphonates, but further studies are needed before general application in the breast cancer population, say researchers.
[More]
Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.
[More]
Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
[More]
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate - a class of drugs that prevent loss of bone mass.
[More]
Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
[More]
Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use.
[More]
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.
[More]
A person has a tumor removed from her femur. A soldier is struck by an improvised explosive device and loses a portion of his tibia. A child undergoes chemotherapy for osteosarcoma but part of the bone dies as a result.
[More]
An FDA panel of oncologists has voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.
[More]